Cancer Tumor Profiling Market - 2024-2033

July 2025 | 207 pages | ID: CA3D17F112F3EN
DataM Intelligence

Abstracts

The Cancer Tumor Profiling Market was valued at US$ 10.98 Billion in 2024 and is anticipated to reach US$ 24.62 Billion by 2033, at a CAGR of 0.095 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Tumor Profiling Market.

This report delivers a comprehensive overview of the Cancer Tumor Profiling Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Tumor Profiling Market. The Cancer Tumor Profiling Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Cancer Tumor Profiling Market Scope:

Key Players

• F. Hoffmann-La Roche Ltd.
• Mergers & Acquisitions
• Key Product Development Activities
• Regulatory Approvals, etc.
• Illumina, Inc.
• Myriad Genetics, Inc
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Caris Life Sciences.
• Guardant Health
• NanoString Technologies (a Bruker Company)
• Foundation Medicine, Inc.
• Paragon Genomics, Inc.

Major Highlights

This report delivers a comprehensive overview of the Cancer Tumor Profiling Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Tumor Profiling Market. The Cancer Tumor Profiling Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Cancer Type
2.5. Snippet by Technology Type
2.6. Snippet by Biomarker Type
2.7. Snippet by Application
2.8. Snippet by End-User
2.9. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising Prevalence of Cancer
    3.1.1.2. Technological Advancements in Cancer Tumor Profiling
    3.1.1.3. Rising Adoption of Personalized and Precision Oncology
  3.1.2. Restraints
    3.1.2.1. High Cost Associated with Cancer Tumor Profiling
    3.1.2.2. Data Privacy and Ethical Concerns
    3.1.2.3. Regulatory and Validation Hurdles for Novel Profiling Assays
  3.1.3. Opportunity
    3.1.3.1. Integration of Artificial Intelligence (AI) in Tumor Profiling
    3.1.3.2. Expanding Applications in Rare and Hard-to-Treat Cancers
    3.1.3.3. Growth of Immuno-Oncology and Biomarker-Driven Therapies
  3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established Leaders with the Largest Marketing Brand
  4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Cancer Epidemiology Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics

5. CANCER TUMOR PROFILING MARKET, BY PRODUCT TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  5.1.2. Market Attractiveness Index, By Product Type
5.2. Kits and Consumables*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Devices

6. CANCER TUMOR PROFILING MARKET, BY CANCER TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Breast Cancer*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Leukemias
6.7. Melanoma Cancer
6.8. Others

7. CANCER TUMOR PROFILING MARKET, BY TECHNOLOGY TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassay*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Liquid Biopsy
7.5. Polymerase Chain Reaction
7.6. In-Situ Hybridization
7.7. Microarray
7.8. Others

8. CANCER TUMOR PROFILING MARKET, BY BIOMARKER TYPE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomic Biomarkers*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarkers
8.4. Others

9. CANCER TUMOR PROFILING MARKET, BY APPLICATION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.1.2. Market Attractiveness Index, By Application
9.2. Clinical Applications*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  9.2.3. Diagnostics
  9.2.4. Personalized Medicines
  9.2.5. Others
9.3. Research Applications

10. CANCER TUMOR PROFILING MARKET, BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Pharmaceutical and Biotechnology Companies
10.5. Research and Educational Institutions
10.6. Others

11. CANCER TUMOR PROFILING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.9.1. U.S.
    11.2.9.2. Canada
    11.2.9.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.9.1. Germany
    11.3.9.2. UK
    11.3.9.3. France
    11.3.9.4. Spain
    11.3.9.5. Italy
    11.3.9.6. Rest of Europe
11.4. Asia-Pacific
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.9.1. China
    11.4.9.2. India
    11.4.9.3. Japan
    11.4.9.4. South Korea
    11.4.9.5. Rest of Asia-Pacific
11.5. South America
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.9.1. Brazil
    11.5.9.2. Argentina
    11.5.9.3. Rest of South America
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

12.1. Competitive Overview and Key Market Players
12.2. Market Share Analysis and Positioning Matrix
12.3. Strategic Partnerships, Mergers & Acquisitions
12.4. Key Developments in Product Portfolios and Innovations
12.5. Company Benchmarking

13. COMPANY PROFILES

13.1. F. Hoffmann-La Roche Ltd.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
    13.1.2.1. Product Description
    13.1.2.2. Product Key Performance Indicators (KPIs)
  13.1.3. Financial Overview
    13.1.3.1. Company Revenue
    13.1.3.2. Geographical Revenue Shares
    13.1.3.3. Revenue Forecasts
  13.1.4. Key Developments
13.2. Mergers & Acquisitions
13.3. Key Product Development Activities
13.4. Regulatory Approvals, etc.
13.5. SWOT Analysis
13.6. Illumina, Inc.
13.7. Myriad Genetics, Inc
13.8. Thermo Fisher Scientific Inc.
13.9. Agilent Technologies, Inc.
13.10. Caris Life Sciences.
13.11. Guardant Health
13.12. NanoString Technologies (a Bruker Company)
13.13. Foundation Medicine, Inc.
13.14. Paragon Genomics, Inc. (LIST NOT EXHAUSTIVE)

14. ASSUMPTIONS AND RESEARCH METHODOLOGY

14.1. Data Collection Methods
14.2. Data Triangulation
14.3. Forecasting Techniques
14.4. Data Verification and Validation

15. APPENDIX

15.1. About Us and Services
15.2. Contact Us